TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8223076
Drug: Lactogest (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactogest (2 capsules, approx 3000 IU)
Study: 8223076
Drug: Enzyme treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme treatment (3000 or 6000 IU) with 50 g of lactose
Study: 2433872
Drug: 0.25% methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% methotrexate cream
Study: 30251591
Drug: High-dose ESS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ESS (1-hour daily during hospitalization)
Study: 30251591
Drug: Low-dose ESS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ESS (placebo)
Study: 29064791
Drug: Quercetin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin at a dose of 120 mg per os daily added to standard treatment
Study: 29064791
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without quercetin
Study: 22093961
Drug: Small vessels
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small vessels treatment
Study: 11601562
Drug: Supplement Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement Group (50 mg iron/day as amino acid chelate)
Study: 9744373
Drug: Dorzolamide 2.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2.0% three times daily
Study: 7527106
Drug: Trandolapril 4
Normalized name: trandolapril 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 4 mg o.d.
Study: 6381166
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg b.i.d.
Study: 7527106
Drug: Trandolapril +
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril + HCTZ 25 mg (if needed)
Study: 7527106
Drug: Captopril +
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril + HCTZ 25 mg (if needed)
Study: 2525984
Drug: Etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 200 mg three times a day
Study: 2525984
Drug: Etodolac 300
Normalized name: etodolac 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 300 mg twice a day
Study: 8458044
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg once a day
Study: 2525984
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg three times a day
Study: 31190151
Drug: Tissue-engineered substitute
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-engineered substitute for autologous oral mucosa
Study: 31190151
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of stem cells
Study: 25803571
Drug: Weekly fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly fractionated IPL
Study: 19439758
Drug: Local corticosteroid
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local corticosteroid injection (25 mg prednisolone)
Study: 29072044
Drug: Radial shock
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shock wave therapy
Study: 17270320
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of Tdap and influenza vaccines
Study: 17270320
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of influenza vaccine followed by Tdap
Study: 31187169
Drug: Lapatinib 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 2000 mg
Study: 15826053
Drug: Phloem-fortified rye
Normalized name: Rye
DrugBank: Rye (DB10564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phloem-fortified rye bread (62 mg catechins, high polyphenol, HP)
Study: 15826053
Drug: Phloem-fortified rye
Normalized name: Rye
DrugBank: Rye (DB10564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phloem-fortified rye bread (31 mg catechins, low polyphenol, LP)
Study: 6125185
Drug: Atenolol 60
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 60 mg
Study: 6125185
Drug: Fenoterol (inhaled)
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (inhaled)
Study: 6125185
Drug: Histamine (inhaled)
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine (inhaled)
Study: 26666236
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow cell therapy
Study: 11804978
Drug: Intravenous fibrinolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fibrinolysis with alteplase
Study: 11804978
Drug: Revascularization by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revascularization by stent placement with additional abciximab treatment
Study: 7552860
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg orally, four times daily for 15 days)
Study: 15374509
Drug: Cerebrolysin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin + multivitamin infusions
Study: 15374509
Drug: Multivitamin infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin infusions alone
Study: 6156059
Drug: IV gamma-globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV gamma-globulin (GG) 20 g IV given postoperatively
Study: 30465722
Drug: Dexamethasone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.15 mg/kg)
Study: 14609970
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy plus gradual tapering of benzodiazepines (combined treatment)
Study: 14609970
Drug: Gradual tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual tapering of benzodiazepines only (control group)
Study: 8618283
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (2 cycles of 70 mg/m² cisplatin and 30 mg/m² doxorubicin with a 3-week interval)
Study: 1414144
Drug: G‐DAMME (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐DAMME (0.25 mg iv)
Study: 4022581
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (1% prednisolone acetate) in Group 2
Study: 4022581
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group 1) with cycloplegic and topical antibiotic only
Study: 24251579
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control (addition of an oral glucose-lowering agent or commencement of insulin)
Study: 24251579
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of an oral glucose-lowering agent
Study: 24251579
Drug: Commencement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commencement of insulin
Study: 17931940
Drug: Cr, Er:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr, Er: YSGG laser treatment for 40 seconds
Study: 12044126
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine (2 mg/kg of body weight)
Study: 12044126
Drug: Placebo (lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lidocaine, 2 mg/kg)
Study: 10448262
Drug: Onapristone 100
Normalized name: Onapristone
DrugBank: Onapristone (DB12637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onapristone 100 mg/day
Study: 7884433
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and cyclophosphamide combination therapy
Study: 17577460
Drug: Doxazosin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin monotherapy
Study: 17577460
Drug: Finasteride monotherapy
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride monotherapy
Study: 2551088
Drug: Prophylactic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prophylactic low-dose heparin/dihydroergotamine
Study: 2551088
Drug: Low-molecular heparin/dihydroergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular heparin/dihydroergotamine
Study: 7318622
Drug: Conventional mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional mechanical bowel preparation
Study: 19693492
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg/day)
Study: 15231554
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (psychotherapy + antidepressants)
Study: 11277173
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human thrombopoietin (rhTPO) administered intravenously by bolus injection at doses ranging from 0.3 to 4.8 microg/kg/day every 3 days and 0.6 microg/kg daily to three patients.
Study: 11277173
Drug: G-CSF administered
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administered concomitantly to promote myeloid recovery.
Study: 9863499
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of four virostatics affecting four targets
Study: 9863499
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three virostatics affecting three targets
Study: 9863499
Drug: Shorter (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter (3 week) sequences of drug combinations
Study: 8307046
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g once daily for two days
Study: 8307046
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G standard regimen for six days
Study: 30171341
Drug: Soft laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft laser therapy (15 sessions over 3 weeks)
Study: 30171341
Drug: Shockwave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shockwave therapy (3 treatments over 3 weeks)
Study: 22133037
Drug: Sensor-Augmented Pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-Augmented Pump Therapy (SAPT)
Study: 22133037
Drug: Multiple Daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Daily Injection (MDI) therapy with self-monitoring of blood glucose (SMBG)
Study: 12385596
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg S-PS daily
Study: 12385596
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg S-PS daily
Study: 7481155
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment (various types)
Study: 7481155
Drug: Streptokinase +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase + Aspirin
Study: 7481155
Drug: Streptokinase +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase + Aspirin + Heparin
Study: 7481155
Drug: Aspirin-accelerated t-PA-heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-accelerated t-PA-heparin
Study: 2393076
Drug: Atracurium 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.125 mg/kg after initial dose of Atracurium 0.5 mg/kg
Study: 2393076
Drug: Atracurium 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.125 mg/kg after Alcuronium 0.25 mg/kg
Study: 6778240
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate oral
Study: 28836470
Drug: EMLA 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA 5% cream applied daily for 4 weeks as a primary dressing
Study: 23340894
Drug: IDeg OD
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDeg OD Flex (once-daily insulin degludec with 8-40 hour intervals)
Study: 23340894
Drug: IDeg OD
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDeg OD (once-daily insulin degludec at the main evening meal)
Study: 23340894
Drug: IGlar OD
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGlar OD (once-daily insulin glargine at the same time each day)
Study: 21087125
Drug: Pocket-sized containers
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pocket-sized containers of alcohol-based gel, reminder materials, and education for all healthcare workers (HCWs)
Study: 15558381
Drug: Constraint-Induced Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Therapy (CIT)
Study: 15335180
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of manidipine
Study: 15335180
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of cilnidipine
Study: 11218763
Drug: Intrathecal nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal nicardipine administration (12 ml daily dose, 8 mg of nicardipine for 14 days)
Study: 11218763
Drug: Intrathecal nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal nicardipine administration
Study: 9052891
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg UID)
Study: 9052891
Drug: Nifedipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (60 mg UID)
Study: 9052891
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg BID)
Study: 9052891
Drug: Doxazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (4 mg UID)
Study: 27754805
Drug: Testosterone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (7.5 g of 1% testosterone gel daily for 3 years)
Study: 27754805
Drug: Placebo (gel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gel)
Study: 26328600
Drug: Substitution of
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitution of 100 g/d sugary drinks with 100 g/d milk
Study: 22959781
Drug: Cinacalcet (calcium-sensing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (calcium-sensing receptor agonist)
Study: 16896836
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg meloxicam for 1 month
Study: 16896836
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 1 month
Study: 10655195
Drug: Timolol-pilocarpine fixed
Normalized name: pilocarpine / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol-pilocarpine fixed combination twice daily
Study: 28337899
Drug: Ketoprofen (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (single dose 30 minutes prior to extraction)
Study: 28337899
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug administration before extraction)
Study: 24145423
Drug: Pharmacological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological intervention targeting the neuroactive ligand-receptor interaction gene set
Study: 21390581
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg/(kg·d) for three days)
Study: 21390581
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment and Chinese herbal decoction for purgation)
Study: 19641900
Drug: Anti-psychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-psychotic treatment (duration: 3 weeks)
Study: 19641900
Drug: Anti-psychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-psychotic treatment (duration: 8 weeks)
Study: 19641900
Drug: Anti-psychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-psychotic treatment (duration: 3 and 8 weeks)
Study: 12064377
Drug: Enalapril/Hydrochlorothiazide 20/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril/Hydrochlorothiazide 20/12.5 mg tablets
Study: 12064377
Drug: Control formulation
Normalized name: nut.tx, weight loss-control formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formulation of Enalapril/Hydrochlorothiazide 20/12.5 mg tablets
Study: 6798049
Drug: Mechanical irrigation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical irrigation with a 10% mannitol solution
Study: 6798049
Drug: Conventional preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparations by digestive tract irrigation with or without intestinal antibiotics
Study: 6798049
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of antibiotics (neomycin, metronidazole by mouth)
Study: 6235682
Drug: Combination preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination preparation of benzoyl peroxide and miconazole cream
Study: 6235682
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide and oral tetracycline
Study: 23103906
Drug: Warfarin (Control)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (Control)
Study: 27638053
Drug: 300 IU
Normalized name: Follistim AQ 300 IU per 0.36 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IU of highly purified menotrophin as single subcutaneous and intramuscular doses
Study: 27638053
Drug: 300 IU
Normalized name: Follistim AQ 300 IU per 0.36 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IU of highly purified urofollitrophin as single subcutaneous doses
Study: 27638053
Drug: 225 IU
Normalized name: Ascorbic Acid/Calcium Pantothenate/Cyanocobalamin/Iron/Niacin/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin D/Vitamin E/Zinc 200 MG-18.4 MG-0.005 MG-12 MG-100 MG-4.1 MG-10 MG-0.3 MG-10000 IU-400 IU-225 IU-1.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 IU of hp‐FSH as single subcutaneous doses
Study: 27638053
Drug: daily 225
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: daily 225 IU of hp‐FSH as subcutaneous doses for 5 consecutive days
Study: 25055938
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day plus tegafur-uracil 400 mg/day (TU) for 2 years
Study: 25055938
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus doxorubicin (40 mg/m2) and cyclophosphamide (500 mg/m2) (ACT) for 2 years
Study: 25055938
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day plus tegafur-uracil 400 mg/day (TU)
Study: 10563034
Drug: Alcohol administered
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administered (3 alcoholic drinks each containing approximately 10 g of pure alcohol)
Study: 10563034
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered (equivalent non-alcoholic beverage)
Study: 1684155
Drug: RU 41,656
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 41,656 10 mg
Study: 1684155
Drug: Scopolamine 0.6
Normalized name: scopolamine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.6 mg s.c.
Study: 6355542
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and sulfinpyrazone
Study: 30778028
Drug: Topiramate, up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate, up to 100 mg daily for three months
Study: 24731891
Drug: Lavender inhalation
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender inhalation based on sesame oil
Study: 18930550
Drug: Intraoperative 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative 5-fluorouracil (5-FU) 50 mg/ml for 5 minutes
Study: 11151233
Drug: Intraoperative mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative mitomycin C (MMC) 0.2 mg/ml for 2 minutes
Study: 17215195
Drug: Inulin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (0.25 g/kg/d for 3 weeks)
Study: 15827896
Drug: L-carnitine 20
Normalized name: L-Carnitine 200mg/1mL Solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 20 mg/kg, thrice weekly for 6 months
Study: 9587725
Drug: Tramadol 3
Normalized name: TRAMADOL 300MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 3 mg kg‐1 (n = 20) administered intravenously at the beginning of wound closure
Study: 9587725
Drug: Tramadol 3
Normalized name: TRAMADOL 300MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 3 mg kg‐1 (n = 20)
Study: 8790652
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg on the first day, followed by 100 mg for the next nine days)
Study: 4985446
Drug: Jet injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injection of diluted smallpox vaccine with a titre of 10(7) TCID(50)/ml
Study: 4985446
Drug: Jet injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injection of diluted smallpox vaccine with a titre of 10(6) TCID(50)/ml
Study: 4985446
Drug: Multiple-pressure inoculation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-pressure inoculation of undiluted vaccine